Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
|
5-day change
|
1st Jan Change
|
76.02
USD
|
+0.16%
|
|
+0.65%
|
+22.61%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
805
|
902.1
|
1,956
|
3,439
|
4,246
|
5,269
|
-
|
-
|
Enterprise Value (EV)
1 |
906.1
|
1,041
|
1,956
|
3,439
|
4,246
|
5,269
|
5,269
|
5,269
|
P/E ratio
|
-
|
-
|
-27.3
x
|
127
x
|
13.3
x
|
12.4
x
|
12.6
x
|
9.59
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.32
x
|
2.66
x
|
4.6
x
|
3.68
x
|
3.28
x
|
3.51
x
|
3.35
x
|
2.9
x
|
EV / Revenue
|
2.32
x
|
2.66
x
|
4.6
x
|
3.68
x
|
3.28
x
|
3.51
x
|
3.35
x
|
2.9
x
|
EV / EBITDA
|
9.59
x
|
15.3
x
|
19.6
x
|
7.62
x
|
7.01
x
|
7.39
x
|
7.44
x
|
6.85
x
|
EV / FCF
|
13.8
x
|
230
x
|
-
|
13.1
x
|
-
|
6.78
x
|
7.7
x
|
8.21
x
|
FCF Yield
|
7.25%
|
0.43%
|
-
|
7.66%
|
-
|
14.7%
|
13%
|
12.2%
|
Price to Book
|
7.18
x
|
1.75
x
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
39,248
|
66,871
|
67,691
|
67,493
|
68,489
|
69,313
|
-
|
-
|
Reference price
2 |
20.51
|
13.49
|
28.89
|
50.96
|
62.00
|
76.02
|
76.02
|
76.02
|
Announcement Date
|
2/25/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
347.3
|
339.4
|
425.2
|
935.1
|
1,296
|
1,502
|
1,571
|
1,815
|
EBITDA
1 |
83.96
|
58.87
|
99.71
|
451.3
|
605.6
|
713.2
|
708.6
|
769.2
|
EBIT
1 |
72.38
|
34.18
|
57.79
|
403.4
|
545.6
|
653.1
|
633.9
|
717
|
Operating Margin
|
20.84%
|
10.07%
|
13.59%
|
43.14%
|
42.08%
|
43.48%
|
40.35%
|
39.51%
|
Earnings before Tax (EBT)
1 |
28.63
|
-11.48
|
-75.04
|
26.72
|
410.9
|
533.7
|
560.3
|
807.4
|
Net income
1 |
31.67
|
-13.47
|
-71.28
|
28.07
|
326.7
|
437.1
|
438.9
|
586.4
|
Net margin
|
9.12%
|
-3.97%
|
-16.76%
|
3%
|
25.2%
|
29.1%
|
27.94%
|
32.31%
|
EPS
2 |
-
|
-
|
-1.060
|
0.4000
|
4.650
|
6.132
|
6.025
|
7.928
|
Free Cash Flow
1 |
58.32
|
3.922
|
-
|
263.4
|
-
|
777.1
|
684
|
642
|
FCF margin
|
16.79%
|
1.16%
|
-
|
28.17%
|
-
|
51.74%
|
43.54%
|
35.37%
|
FCF Conversion (EBITDA)
|
69.47%
|
6.66%
|
-
|
58.37%
|
-
|
108.95%
|
96.53%
|
83.46%
|
FCF Conversion (Net income)
|
184.18%
|
-
|
-
|
938.59%
|
-
|
177.79%
|
155.85%
|
109.49%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/25/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
129.6
|
208.9
|
223.7
|
239.3
|
263.2
|
300.8
|
321.7
|
319.9
|
354
|
370
|
377.7
|
374.5
|
383.4
|
371.5
|
379.6
|
EBITDA
1 |
40.4
|
95.79
|
91.91
|
114.4
|
132.2
|
156.6
|
165.8
|
154.2
|
180.8
|
170.7
|
184.4
|
179.6
|
191.1
|
180.7
|
187.7
|
EBIT
1 |
28.2
|
92.69
|
88.61
|
102.2
|
120.4
|
142
|
150.1
|
139.5
|
165.7
|
155.3
|
167.7
|
163.5
|
173
|
154.5
|
161.2
|
Operating Margin
|
21.76%
|
44.37%
|
39.61%
|
42.72%
|
45.73%
|
47.21%
|
46.65%
|
43.61%
|
46.82%
|
41.97%
|
44.41%
|
43.64%
|
45.12%
|
41.6%
|
42.47%
|
Earnings before Tax (EBT)
1 |
-41.01
|
57.9
|
62.04
|
83.02
|
-176.2
|
-11.1
|
123.7
|
160
|
138.4
|
171.3
|
162.3
|
161.3
|
146.6
|
151
|
88.05
|
Net income
1 |
-40.22
|
42.96
|
43.06
|
61.23
|
-119.2
|
-2.807
|
94.13
|
132
|
103.4
|
131.1
|
108.2
|
108.6
|
102.4
|
112.5
|
67.53
|
Net margin
|
-31.04%
|
20.57%
|
19.25%
|
25.59%
|
-45.29%
|
-0.93%
|
29.26%
|
41.24%
|
29.2%
|
35.43%
|
28.66%
|
29%
|
26.7%
|
30.29%
|
17.79%
|
EPS
2 |
-0.5900
|
0.6100
|
0.6100
|
0.8600
|
-1.740
|
-0.0400
|
1.330
|
1.880
|
1.470
|
1.870
|
1.526
|
1.520
|
1.414
|
1.563
|
0.9200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
4/29/22
|
8/4/22
|
11/3/22
|
2/23/23
|
5/4/23
|
8/3/23
|
11/2/23
|
2/22/24
|
5/2/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
101
|
139
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
1.205
x
|
2.358
x
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
58.3
|
3.92
|
-
|
263
|
-
|
777
|
684
|
642
|
ROE (net income / shareholders' equity)
|
50.6%
|
8.21%
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
2.860
|
7.690
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
0.3000
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
22.1
|
12.5
|
-
|
18.3
|
46.6
|
51.3
|
59.8
|
72
|
Capex / Sales
|
6.35%
|
3.68%
|
-
|
1.96%
|
3.59%
|
3.41%
|
3.8%
|
3.97%
|
Announcement Date
|
2/25/20
|
2/25/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Last Close Price
76.02
USD Average target price
104.9
USD Spread / Average Target +37.99% Consensus |
1st Jan change
|
Capi.
|
---|
| +22.61% | 5.27B | | -1.29% | 12.64B | | -0.47% | 8.46B | | -2.03% | 4.49B | | -53.56% | 3.11B | | +19.30% | 2.87B | | +33.07% | 2.31B | | -8.42% | 2.23B | | -3.55% | 1.89B | | +5.37% | 1.64B |
Diagnostic & Testing Substances
|